https://www.selleckchem.com/pr....oducts/geneticin-g41
01). The main reasons for the alitretinoin cessation in the poor-compliance group were insufficient response (40.8%), followed by high cost (34.7%), and adverse events (24.5%). Alitretinoin appears the preferred long-term treatment option for CHE. Although there are complaints about late efficacy, cost, and side effects, following proper explanation, these should not justify discontinuation. need to recognize the reasons for poor compliance with alitretinoin for each patient and suggest continuing alitretinoin for the suc
Like
Comment
Share
